The Peptide Therapeutics Contract API Manufacturing Market Size is valued at USD 2.36 billion in 2023 and is predicted to reach USD 3.77 billion by the year 2031 at a 6.3% CAGR during the forecast period for 2024-2031.
Peptide therapeutics contract API manufacturing is a technique of extending the production of drugs with active pharmaceutical components (APIs) or the parts that provide an external entity with the desired results. The increasing need for peptide therapies to treat the rising incidence of aggressive cancer diseases globally has led businesses in the peptide therapeutics contract API manufacturing industry to increase their capacity for production. As part of their efforts to raise consciousness, they additionally collaborate with oncology institutions. Peptide therapeutics contract API manufacturing popularity has expanded due to preferences for peptide-based drugs. In order to enable more rapid and efficient APIs, a number of breakthroughs in technology are also being developed.
However, the challenges of complying with regulations are impeding the expansion of the Peptide Contract API production sector. Also, the main challenges in API peptide production are preserving the structural integrity of the molecules and ensuring accurate dosing. These biologics are highly sensitive and prone to degradation, which makes it challenging to formulate and deliver them effectively. Advancements in drug design have resulted in the creation of novel drug molecules in the form of API peptides. Due to their substantial therapeutic potential, market opportunities, and economic value, it is expected that therapeutic peptides will attract continued investment and research, driving long-term success.
Competitive Landscape
Some of the major key players in the peptide therapeutics contract API manufacturing market are,
- Ambiopharm Inc
- Auspep
- Bachem Holding AG
- BCN Peptides
- Chinese Peptide Company
- CordenPharma
- CPC Scientific
- Creative Peptides
- CSBio
- Hybio Pharmaceutical
- Peptide Institute, Inc.
- PolyPeptide Group
- ScinoPharm
- Senn Chemicals AG
Market Segmentation:
The peptide therapeutics contract API manufacturing market is segmented based on scale of operation, type of synthesis method used, and enterprise type. Based on the scale of operation, the market is segmented into preclinical/clinical and commercial. By synthesis method used, the market is segmented into non-chemical synthesis method and chemical synthesis method. By enterprise type, the market is segmented into large enterprises and small and medium enterprises.
Based on the Enterprise Type, the Small and Medium Enterprise Peptide Therapeutics Contract API Manufacturing Market Segment is Accounted as a Major Contributor to the Peptide Therapeutics Contract API Manufacturing Market
The small and medium enterprise peptide therapeutics contract API manufacturing market will hold a major global market share in 2023. Increasing recognition of the significance of data security and encryption has led smaller organizations to look for flexible, affordable solutions to protect their sensitive data from internet threats. The resources and expertise required to manage the institution's primary administrative processes properly often need to be improved in SMEs.
Chemical Synthesis Segment to Witness Growth at a Rapid Rate
The chemical synthesis industry uses bulk peptide therapeutics contract API manufacturing because chemical synthesis allows researchers to produce new substances with special qualities. Chemical synthesis has also enabled the development of numerous commercially significant goods, such as pharmaceuticals, polymers, and high-quality majority chemicals, especially in countries like the US, Germany, the UK, China, and India.
In the region, the North American Peptide Therapeutics Contract API Manufacturing Market holds a significant revenue share
The North American peptide therapeutics contract API manufacturing market is expected to register the highest market share in revenue in the near future. This can be attributed to the rise in the spending of big businesses. Additionally, it is anticipated that rising medical costs and greater awareness of cutting-edge peptide medicines will fuel the growth of the local peptide therapeutics contract API manufacturing business. In addition, Asia Pacific is projected to grow rapidly in the global peptide therapeutics contract API manufacturing industry because there is a steady presence of key players. Peptide therapies contract API manufacturing will grow in the region as a result of increased awareness of easily accessible peptide production methods and increased emphasis on introducing peptide drugs to the commercial sector.
Peptide Therapeutics Contract API Manufacturing Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.36 Bn |
|
Revenue Forecast In 2031 |
USD 3.77 Bn |
|
Growth Rate CAGR |
CAGR of 6.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Scale Of Operation, Type of Synthesis Method Used, And Enterprise Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Ambiopharm Inc, Auspep, Bachem Holding AG, BCN Peptides, Chinese Peptide Company, CordenPharma, CPC Scientific, Creative Peptides, CSBio, Hybio Pharmaceutical, Peptide Institute, Inc., PolyPeptide Group, ScinoPharm, and Senn Chemicals AG. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
